Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I

Ken Overture, Muhsen Al-Dhalimy, Kara Manning, Ching Nan Ou, Milton Finegold, Markus Grompe

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Previously, this lab has reported the use of hepatocyte transplantation and in vivo gene therapy for the correction of a mouse model of Hereditary Tyrosinemia Type I (HT1). Here, we demonstrate repopulation of fumarylacetoacetate hydrolase (FAH)-deficient livers with cultured hepatocytes. Correction of the disease phenotype was achieved by retrovirally transducing cultured FAH- hepatocytes ex vivo, followed by transplantation and selective repopulation. Treated mice were phenotypically normal and had corrected plasma amino acid levels and liver function tests. Our results demonstrate that efficient hepatic repopulation using ex vivo genetically manipulated hepatocytes is feasible.

Original languageEnglish (US)
Pages (from-to)295-304
Number of pages10
JournalHuman Gene Therapy
Volume9
Issue number3
StatePublished - Feb 10 1998

Fingerprint

Tyrosinemias
Genetic Therapy
Hepatocytes
Liver
Transplantation
Liver Function Tests
Phenotype
Amino Acids

ASJC Scopus subject areas

  • Genetics

Cite this

Overture, K., Al-Dhalimy, M., Manning, K., Ou, C. N., Finegold, M., & Grompe, M. (1998). Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I. Human Gene Therapy, 9(3), 295-304.

Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I. / Overture, Ken; Al-Dhalimy, Muhsen; Manning, Kara; Ou, Ching Nan; Finegold, Milton; Grompe, Markus.

In: Human Gene Therapy, Vol. 9, No. 3, 10.02.1998, p. 295-304.

Research output: Contribution to journalArticle

Overture, K, Al-Dhalimy, M, Manning, K, Ou, CN, Finegold, M & Grompe, M 1998, 'Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I', Human Gene Therapy, vol. 9, no. 3, pp. 295-304.
Overture K, Al-Dhalimy M, Manning K, Ou CN, Finegold M, Grompe M. Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I. Human Gene Therapy. 1998 Feb 10;9(3):295-304.
Overture, Ken ; Al-Dhalimy, Muhsen ; Manning, Kara ; Ou, Ching Nan ; Finegold, Milton ; Grompe, Markus. / Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I. In: Human Gene Therapy. 1998 ; Vol. 9, No. 3. pp. 295-304.
@article{4f9ffe609f414210a77bfc38cad4a635,
title = "Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I",
abstract = "Previously, this lab has reported the use of hepatocyte transplantation and in vivo gene therapy for the correction of a mouse model of Hereditary Tyrosinemia Type I (HT1). Here, we demonstrate repopulation of fumarylacetoacetate hydrolase (FAH)-deficient livers with cultured hepatocytes. Correction of the disease phenotype was achieved by retrovirally transducing cultured FAH- hepatocytes ex vivo, followed by transplantation and selective repopulation. Treated mice were phenotypically normal and had corrected plasma amino acid levels and liver function tests. Our results demonstrate that efficient hepatic repopulation using ex vivo genetically manipulated hepatocytes is feasible.",
author = "Ken Overture and Muhsen Al-Dhalimy and Kara Manning and Ou, {Ching Nan} and Milton Finegold and Markus Grompe",
year = "1998",
month = "2",
day = "10",
language = "English (US)",
volume = "9",
pages = "295--304",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I

AU - Overture, Ken

AU - Al-Dhalimy, Muhsen

AU - Manning, Kara

AU - Ou, Ching Nan

AU - Finegold, Milton

AU - Grompe, Markus

PY - 1998/2/10

Y1 - 1998/2/10

N2 - Previously, this lab has reported the use of hepatocyte transplantation and in vivo gene therapy for the correction of a mouse model of Hereditary Tyrosinemia Type I (HT1). Here, we demonstrate repopulation of fumarylacetoacetate hydrolase (FAH)-deficient livers with cultured hepatocytes. Correction of the disease phenotype was achieved by retrovirally transducing cultured FAH- hepatocytes ex vivo, followed by transplantation and selective repopulation. Treated mice were phenotypically normal and had corrected plasma amino acid levels and liver function tests. Our results demonstrate that efficient hepatic repopulation using ex vivo genetically manipulated hepatocytes is feasible.

AB - Previously, this lab has reported the use of hepatocyte transplantation and in vivo gene therapy for the correction of a mouse model of Hereditary Tyrosinemia Type I (HT1). Here, we demonstrate repopulation of fumarylacetoacetate hydrolase (FAH)-deficient livers with cultured hepatocytes. Correction of the disease phenotype was achieved by retrovirally transducing cultured FAH- hepatocytes ex vivo, followed by transplantation and selective repopulation. Treated mice were phenotypically normal and had corrected plasma amino acid levels and liver function tests. Our results demonstrate that efficient hepatic repopulation using ex vivo genetically manipulated hepatocytes is feasible.

UR - http://www.scopus.com/inward/record.url?scp=0032501987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032501987&partnerID=8YFLogxK

M3 - Article

C2 - 9508047

AN - SCOPUS:0032501987

VL - 9

SP - 295

EP - 304

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -